# US 2025/0144166 A1 · Compositions and methods for inhibiting rho kinase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144166 A1
- Document ID: US20250144166A1
- Status: Published application
- Kind: A1
- Application number: 18/836,845
- Filed: 2023-02-09
- Published: 2025-05-08
- Earliest claimed: 2022-02-09
- Assignees: Interlude Biopharma Co.; University of Maryland, College Park
- Applicants: Interlude Biopharma Co.; University of Maryland, College Park
- Inventors: Younggeon JIN; Nir BARAK; Jain KIM
- Web page: https://patentgrep.com/patent/US20250144166A1

## CPC

- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61K 9/0043: {Nose}
- A61K 9/0046: {Ear}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides for compositions and methods for treating a condition characterized by Rho-associated coiled-coil kinase (ROCK) activity in a subject in need thereof via administration of an effective amount of larazotide or larazotide derivative, or pharmaceutically acceptable salt thereof, to said subject in an amount and manner effective to inhibit ROCK activity in a tissue.

## Claims

### Claim 1

A method for treating a subject for a condition characterized by Rho-associated coiled-coil kinase (ROCK) activity, comprising:
administering an effective amount of larazotide or larazotide derivative, or pharmaceutically acceptable salt thereof, to said subject in an amount and manner effective to inhibit ROCK activity in a tissue.

### Claim 2 (depends on 1)

The method of claim 1, wherein the tissue is the gastrointestinal tract.

### Claim 3 (depends on 2)

The method of claim 2, wherein the condition is selected from cancer, adenoma, celiac disease, inflammatory bowel disease (IBD), Crohn's Disease, Ulcerative Colitis, environmental enteropathy, esophagitis, necrotizing enterocolitis, intestinal ischemia, inflammatory liver disease, kidney disease, pancreatitis, hyperglycemia, and pulmonary or cardiac inflammation or fibrosis.

### Claim 4 (depends on 3)

The method of claim 3, wherein the cancer originates from any tissue, optionally wherein the cancer originates from skin, colon, breast, lung, brain, bone, pancreas, kidney, liver, bladder, ovaries, testes, or prostate.

### Claim 5 (depends on 3)

The method of claim 3, wherein the cancer is optionally colorectal cancer, leukemia, myeloma, or lymphoma.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject is at risk for colorectal cancer.

### Claim 7 (depends on 6)

The method of claim 6, wherein the subject's family history, genetic mutations, and/or health history increases the risk for colorectal cancer.

### Claim 8 (depends on 7)

The method of claim 7, wherein a member of the subject's family has or had familial adenomatous polyposis (FAP), hereditary non-polyposis colorectal cancer (HNPCC), Peutz-Jeghers syndrome, or MUTYH-associated polyposis (MAP).

### Claim 9 (depends on 7)

The method of claim 7, wherein the subject has a mutation of one or more genes selected from APC, MLH1, MSH2, MSH6, PMS2, EPCAM, STK11 (LKB1), and MUTYH that increases risk for colorectal cancer.

### Claim 10 (depends on 6, 7, 8, 9)

The method of any one of claims 6 to 9, wherein the subject has one or more single-nucleotide polymorphisms (SNPs) selected from rs6983267, rs4939827, rs3802842, rs16892766, rs10795668, rs4444235, rs10411210, rs6691170, rs4925386, rs3824999, rs647161, rs2423279, rs3217810, and rs59336.

### Claim 11 (depends on 1)

The method of claim 1, wherein the tissue is cancer, which is optionally primary or metastatic cancer.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cancer is selected from lung cancer, breast cancer, kidney cancer, liver cancer, prostate cancer, cervical cancer, colorectal cancer, pancreatic cancer, melanoma, ovarian cancer, bone cancer, urothelial cancer, gastric cancer, head and neck cancer, glioblastoma, head and neck squamous cell carcinoma (HNSCC), non-small cell lung carcinoma (NSCLC), small cell lung cancer (SCLC), bladder cancer, hormone-refractory prostate cancer, and lymphoma.

### Claim 13 (depends on 11, 12)

The method of claim 11 or 12, wherein the tissue is metastatic cancer.

### Claim 14 (depends on 13)

The method of claim 13, wherein the patient has metastatic melanoma.

### Claim 15 (depends on 11, 12, 13, 14)

The method of any one of claims 11 to 14, wherein the cancer is sarcoma or carcinoma.

### Claim 16 (depends on 11, 12, 13, 14, 15)

The method of any one of claims 11 to 15, wherein the subject is undergoing or has undergone a cancer treatment selected from one or more of chemotherapy, radiation, resection, and immunotherapy and immune-oncology agents, optionally wherein the cancer immunotherapy is therapy with an immune checkpoint inhibitor.

### Claim 17 (depends on 11, 12, 13, 14, 15, 16)

The method of any one of claims 11 to 16, wherein the larazotide or larazotide derivative is formulated for intratumoral administration.

### Claim 18 (depends on 1)

The method of claim 1, wherein the tissue is the eye.

### Claim 19 (depends on 18)

The method of claim 18, wherein the larazotide or larazotide derivative is formulated for ophthalmic administration, optionally to the ocular surface or intraocular administration to the back of the eye.

### Claim 20 (depends on 1)

The method of claim 1, wherein the larazotide or larazotide derivative is formulated for administration to the nasal and/or sinus cavity.

### Claim 21 (depends on 1)

The method of claim 1, wherein the larazotide or larazotide derivative is formulated for administration to the ear canal.

### Claim 22 (depends on 1)

The method of claim 1, wherein the tissue is the respiratory tract, and the subject optionally has a condition selected from asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, cystic fibrosis, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), emphysema, bronchitis, pneumonia, lung cancer, and respiratory infection.

### Claim 23 (depends on 22)

The method of claim 22, wherein the larazotide or larazotide derivative is formulated for administration as a solution aerosol or powder to the lungs.

### Claim 24

The method of clam 1, wherein the tissue is the vasculature, and the subject optionally has a condition selected from cardiac fibrosis, cardiac hypertrophy, hypertension, pulmonary hypertension, angina pectoris, vasospastic angina, heart failure, and stroke.

### Claim 25 (depends on 24)

The method of claim 24, wherein the larazotide or larazotide derivative is formulated for pulmonary administration.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1 to 25, wherein the subject has a ROCK mutation selected from one or more of Val1309, Tyr405, Ser1126, Pro1193S, relative to ROCK1 isoform, and/or Thr431Asn, Asp601 Val, and Lys1083Met, relative to ROCK2 isoform.

### Claim 27

The method of any one of the preceding claims, wherein the subject is administered larazotide derivative, or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 27)

The method of claim 27, wherein the larazotide derivative comprises one or more modifications that increase ROCK inhibitor activity as compared to larazotide.

### Claim 29 (depends on 27)

The method of claim 27, wherein the larazotide derivative comprises at least one, at least two, at least three, at least four, at least five D-amino acids.

### Claim 30 (depends on 29)

The method of claim 29, wherein each amino acid of the larazotide derivative (other than Gly) is a D-amino acid, and the derivative is optionally a retro-inverso larazotide.

### Claim 31

The method of any one of the preceding claims, wherein the larazotide or larazotide derivative is locally administered to the tissue.

### Claim 32

A pharmaceutical composition comprising an effective amount of a peptide having the amino acid sequence Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (SEQ ID NO: 1) for inhibiting ROCK activity in a tissue, or a pharmaceutically acceptable salt thereof, and a pharmaceutically-acceptable carrier.
